Vaxcyte (NASDAQ:PCVX) Posts Quarterly Earnings Results

Vaxcyte (NASDAQ:PCVX) posted its earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14, Zacks reports.

Vaxcyte Trading Down 2.9 %

Shares of Vaxcyte stock traded down $2.33 on Tuesday, reaching $79.35. 1,336,624 shares of the stock were exchanged, compared to its average volume of 1,086,481. The firm has a market capitalization of $9.89 billion, a PE ratio of -17.25 and a beta of 0.98. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The business has a fifty day moving average price of $85.46 and a two-hundred day moving average price of $94.99.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PCVX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Vaxcyte in a report on Tuesday, February 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $127.71.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $92.25, for a total transaction of $218,263.50. Following the completion of the sale, the chief executive officer now directly owns 136,215 shares in the company, valued at approximately $12,565,833.75. This trade represents a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total value of $457,450.00. Following the sale, the senior vice president now owns 28,697 shares in the company, valued at approximately $2,625,488.53. The trade was a 14.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 76,616 shares of company stock valued at $6,766,481. 3.10% of the stock is owned by corporate insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.